RESUMO
Optimization of the amino acid residue within a series of anthranilimide-based glycogen phosphorylase inhibitors is described. These studies culminated in the identification of anthranilimides 16 and 22 which displayed potent in vitro inhibition of GPa in addition to reduced inhibition of CYP2C9 and excellent pharmacokinetic properties.
Assuntos
Hidrocarboneto de Aril Hidroxilases/antagonistas & inibidores , Ácidos Carboxílicos/química , Química Farmacêutica/métodos , Diabetes Mellitus Tipo 2/tratamento farmacológico , Glicogênio Fosforilase/antagonistas & inibidores , Imidas/farmacologia , ortoaminobenzoatos/farmacologia , Animais , Hidrocarboneto de Aril Hidroxilases/química , Cristalografia por Raios X , Citocromo P-450 CYP2C9 , Cães , Desenho de Fármacos , Glicina/química , Glicogênio Fosforilase/metabolismo , Humanos , Imidas/química , Concentração Inibidora 50 , Fígado/enzimologia , Conformação Molecular , Ratos , ortoaminobenzoatos/químicaRESUMO
The first report on the identification and structure-activity relationships of a novel series of GPR40 agonists based on a 3-(4-{[N-alkyl]amino}phenyl)propanoic acid template is described. Structural modifications to the original screening hit yielded compounds with a 100-fold increase in potency at the human GPR40 receptor and pEC(50)s in the low nanomolar range. The carboxylic acid moiety is not critical for activity but typically elicits an agonistic response higher than those observed with carboxamide replacements. These compounds may prove useful in unraveling the therapeutic potential of this receptor for the treatment of Type 2 diabetes.